PHILADELPHIA, Oct. 16, 2020 /PRNewswire/ -- Enterin, Inc., a privately held, CNS-focused pharmaceutical company based in Philadelphia and developing novel compounds to treat neurodegenerative diseases, announces the appointment of David McCullough as Chief Executive Officer.
With over 30 years of pharma/biotech experience, Mr. McCullough is a demonstrated strategic, creative, and accomplished leader. With executive and board director experience in startup and established companies, David brings expertise in both the private and public sector. He has a deep understanding of drug development, clinical and regulatory strategy, commercial, finance, IP, manufacturing and operations. Mr. McCullough has a proven track record of building highly skilled, energetic, cross-functional teams both domestically and globally. He has strong experience moving products from early development to launch, including orphan drugs and billion-dollar brands. At Merck, he played a lead role in the $13.5B acquisition of Serono Biotech, and he was honored by the Merck family as a top contributor in corporate development. Additionally, Mr. McCullough has held leadership positions in Allergopharma/EMD Serono and BioCryst. He is interested in Enterin as he has a personal passion for the neurodegenerative therapeutic area and the patient population that can be served with better therapeutic outcomes. "I am thrilled to have the opportunity to join this team that is pioneering the science behind truly innovative approaches in the treatment of neurodegenerative diseases," says McCullough.
More on The PennZone
Enterin's founders and chairmen, Michael Zasloff, MD, PhD and Denise Barbut MD, FRCP reciprocated the sentiment. They said, "We are delighted that David has agreed to join Enterin. His extensive experience in the pharmaceutical industry will supplement the scientific and medical expertise of the existing management team."
About Enterin Inc.
Enterin Inc. is the first company to develop novel compounds that repair the dysfunctional gut-brain axis in patients with neurodegenerative diseases. Enterin Inc. is pioneering the medical community's understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut and the early onset and chronic progression of neurodegenerative disease. The lead compound, ENT-01, displaces membrane-bound alpha-synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson's disease. Enterin Inc. is now progressing ENT-01 through clinical trials in an attempt to reverse the neurologic symptoms of Parkinson's disease.
More on The PennZone
For more information, please visit www.enterininc.com.
Contact
Enterin Inc.
[email protected]
Related Images
enterin-logo.jpg
Enterin Logo
SOURCE Enterin Inc.
With over 30 years of pharma/biotech experience, Mr. McCullough is a demonstrated strategic, creative, and accomplished leader. With executive and board director experience in startup and established companies, David brings expertise in both the private and public sector. He has a deep understanding of drug development, clinical and regulatory strategy, commercial, finance, IP, manufacturing and operations. Mr. McCullough has a proven track record of building highly skilled, energetic, cross-functional teams both domestically and globally. He has strong experience moving products from early development to launch, including orphan drugs and billion-dollar brands. At Merck, he played a lead role in the $13.5B acquisition of Serono Biotech, and he was honored by the Merck family as a top contributor in corporate development. Additionally, Mr. McCullough has held leadership positions in Allergopharma/EMD Serono and BioCryst. He is interested in Enterin as he has a personal passion for the neurodegenerative therapeutic area and the patient population that can be served with better therapeutic outcomes. "I am thrilled to have the opportunity to join this team that is pioneering the science behind truly innovative approaches in the treatment of neurodegenerative diseases," says McCullough.
More on The PennZone
- INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Evolus, Inc. (EOLS) Investors
- DEADLINE REMINDER: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Pintec Technology Holdings Limited (PT)
- All of the "Favorite Brands" - Scrubs 2020
- INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of First American Financial Corporation (FAF) on Behalf of Investors
- TVS Inspirational Network Adds Faith Based Classic TV Shows to Post Cable Network
Enterin's founders and chairmen, Michael Zasloff, MD, PhD and Denise Barbut MD, FRCP reciprocated the sentiment. They said, "We are delighted that David has agreed to join Enterin. His extensive experience in the pharmaceutical industry will supplement the scientific and medical expertise of the existing management team."
About Enterin Inc.
Enterin Inc. is the first company to develop novel compounds that repair the dysfunctional gut-brain axis in patients with neurodegenerative diseases. Enterin Inc. is pioneering the medical community's understanding of the link between infections, dysfunction of the enteric nervous system (ENS) of the gut and the early onset and chronic progression of neurodegenerative disease. The lead compound, ENT-01, displaces membrane-bound alpha-synuclein (αS) aggregates from nerve cells in the ENS and improves neural signaling between the gut and the brain in preclinical models of Parkinson's disease. Enterin Inc. is now progressing ENT-01 through clinical trials in an attempt to reverse the neurologic symptoms of Parkinson's disease.
More on The PennZone
- Pennsylvania: Wolf Administration Encourages Participation in National Prescription Drug Take-Back Day
- Why You Need to Toss Your Scrubs & Buy New
- CEO Coaching International Congratulates Client Criterion HCM on Top Workplaces Title
- Ansys Receives Two TSMC Open Innovation Platform Partner of the Year Awards
- TomCat Films ignites the fireplace video category with 'My Fireplace Girl' series of DVDs and Streaming Videos
For more information, please visit www.enterininc.com.
Contact
Enterin Inc.
[email protected]
Related Images
enterin-logo.jpg
Enterin Logo
SOURCE Enterin Inc.
Filed Under: Business
0 Comments
Latest on The PennZone
- TVS Select Network to Fill Quibi Gap With Free Mobile Program Focus on WatchYour.TV Platform
- Dental Implants in Springfield Start at Only $750
- KDG Named a Top 2020 B2B Company by Clutch.co
- Freya Systems Takes Off As One Of Philadelphia100®'s Fastest Growing Companies
- Pharmaceutical Giant Mallinckrodt Bankruptcy Threatens Lawsuit Filed by Local Unions and Delaware Valley Health Care Coalition, Worth Hundreds of Millions of Dollars
- Longstanding Viera/Suntree brokerage Vista Florida Realty LLC merges with Dale Sorensen Real Estate, Inc
- Hilco Redevelopment Partners to Invest Hundreds of Millions of Dollars to Decommission, Demolish and Remediate the Former PES Refinery Site in Southwest Philadelphia
- Lehigh Valley Orthodontist Offering Braces in Easton for Only $3,995, No Hidden Fees
- Pennsylvania: Governor Wolf Announces $181 Million Investment in Water Infrastructure Projects in 12 Counties
- Michael Meyer Hosts Virtual Event on Communication
- TVS Television Network.Com Adds Iconic Classic TV Series For Post Cable Network Service
- BeBop Sensors' Forte Data Glove Adds Haptic Interaction Support for Oculus 2 and Unreal Engine
- LYRIC names Toni Newman as New Interim Executive Director and Jodi Schwartz as President
- Pennsylvania American Water President Mike Doran Joins Pittsburgh Works Together Board of Directors
- BitRouter Announces Dihedral Software Release for its ATSC3pro Receiver at NAB Show New York
- High School Responder President and Founder Barbara A. Grimm Announces the Launch of High School Responder™ and Appoints Fintech Pioneer Edwin P. Baldry as Chairman of the Board
- Radian to Webcast Third Quarter Conference Call
- Braeden Lichti - What's Next for the Healthcare Sector?
- Scottsdale Plastic Surgeon Dr. Patti Flint now offering sought-after lip lift procedure
- Entrepreneur, Investor Signs $100,000 Contract With Hotel To Host First Female Founders Pitch Summit Despite Pandemic